title: American Society of Clinical Oncology 41st annual meeting.
abstract: For many years the annual meeting of the American Society of Clinical Oncology (ASCO) has been the premier meeting in clinical oncology, and one that is closely scrutinised by Wall Street and international investors because of the economic significance of cancer therapies to the pharmaceutical and biotechnology industries. The area of biologicals and targeted therapies exploded in the late 1990s after the blockbuster results with the monoclonal antibody rituximab in the treatment of lymphoma. Although historically a somewhat conservative organisation that is still closely tied to classical cytotoxic chemotherapy, ASCO has been able to integrate various areas of biological therapy into its scope of clinical activity. Although ASCO still has 'American' in its title, it is really the 'International' Society of Clinical Oncology, as reflected by the attendance at this year's meeting by approximately 30,000, with approximately two-thirds attending from outside the US. There were 9708 abstracts published in conjunction with the meeting, 86 of which are referenced in this review. There were 10 papers chosen for plenary presentations and many other key papers were presented at other oral abstract sessions and poster discussion session that were organised by tumour type. In addition to key papers submitted by specific tumour type, for this year's meeting there were 103 abstracts published in the session entitled 'Developmental Therapeutics: Immunotherapy', and 218 in the session entitled Developmental Therapeutics: Molecular Targets', for a total of 321 biological therapy abstracts compared with only 125 abstracts for the session entitled 'Developmental Therapeutics: Cytotoxic Therapy'. This meeting review is organised by biotherapy modality rather than tumour type.
authors.affiliation: Hoag Cancer Center, Newport Beach, CA 92658, USA.
authors.forename: Robert O
authors.initials: RO
authors.lastname: Dillman
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003226:Congresses as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008495:Medical Oncology; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D061988:Proteasome Inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic; D012955:Societies, Medical; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D061988:Proteasome Inhibitors; D011505:Protein-Tyrosine Kinases